Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis

被引:69
作者
Ragni, M
Cirillo, P
Pascucci, I
Scognamiglio, A
DAndrea, D
Eramo, N
Ezekowitz, MD
Pawashe, AB
Chiariello, M
Golino, P
机构
[1] UNIV NAPLES, SCH MED 2, DIV CARDIOL, DEPT INTERNAL MED, I-80131 NAPLES, ITALY
[2] YALE UNIV, DEPT INTERNAL MED, DIV CARDIOL, NEW HAVEN, CT USA
关键词
thrombolysis; tissue factor; coagulation;
D O I
10.1161/01.CIR.93.10.1913
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Tissue factor (TF)-dependent activation of the coagulation is important in the pathophysiology of intravascular thrombus formation. We tested the effects of a monoclonal antibody against TF (AP-1) on lysis time induced by tissue-type plasminogen activator (TPA) and on reocclusion rate in a rabbit model of carotid artery thrombosis. Methods and Results Intravascular thrombosis was obtained by placing an external constrictor around carotid arteries with endothelial injury. Carotid blood flow velocity was measured continuously with a Doppler flow probe. Thirty minutes after thrombus formation, the rabbits received either AP-1 (0.15 mg/kg IV, n = 8) or placebo (n = 8). All rabbits also received TPA (80 mu g/kg bolus plus 8 mu g . kg(-1). min(-1) infusion for up to 90 minutes or until reperfusion was achieved) and heparin (200 U/kg IV as a bolus). At reperfusion, TPA was discontinued, and the rabbits were followed for an additional 90 minutes. AP-1 shortened lysis time from 44 +/- 8 minutes (mean +/- SEM) in control rabbits to 26 +/- 7 minutes in AP-1-treated rabbits (P < .01). Reocclusion occurred in all control rabbits in 10 +/- 3 minutes, whereas it occurred in only two of eight AP-1-treated rabbits in 72 and 55 minutes (P < .01). No changes in prothrombin time and ex vivo platelet aggregation in response to various agonists were observed after AP-1 administration, indicating the absence of systemic effects by this antibody. Conclusions TF exposure and activation of the extrinsic coagulation pathway play an important role in prolonging lysis time and mediating reocclusion after thrombolysis in this model. AF-1, a monoclonal antibody against TF, might be suitable as adjunctive therapy to TPA.
引用
收藏
页码:1913 / 1918
页数:6
相关论文
共 34 条
[1]   DIFFERENTIAL EXPRESSION OF TISSUE FACTOR PROTEIN IN DIRECTIONAL ATHERECTOMY SPECIMENS FROM PATIENTS WITH STABLE AND UNSTABLE CORONARY SYNDROMES [J].
ANNEX, BH ;
DENNING, SM ;
CHANNON, KM ;
SKETCH, MH ;
STACK, RS ;
MORRISSEY, JH ;
PETERS, KG .
CIRCULATION, 1995, 91 (03) :619-622
[2]  
[Anonymous], 1986, LANCET, V1, P397
[3]   RECOVERY OF LEFT-VENTRICULAR SEGMENTAL FUNCTION AFTER LONG-TERM REPERFUSION FOLLOWING TEMPORARY CORONARY-OCCLUSION IN CONSCIOUS DOGS - COMPARISON OF 2-HOUR AND 4-HOUR OCCLUSIONS [J].
BUSH, LR ;
BUJA, LM ;
SAMOWITZ, W ;
RUDE, RE ;
WATHEN, M ;
TILTON, GD ;
WILLERSON, JT .
CIRCULATION RESEARCH, 1983, 53 (02) :248-263
[4]   EFFECTS OF PROPRANOLOL AND DILTIAZEM ALONE AND IN COMBINATION ON THE RECOVERY OF LEFT-VENTRICULAR SEGMENTAL FUNCTION AFTER TEMPORARY CORONARY-OCCLUSION AND LONG-TERM REPERFUSION IN CONSCIOUS DOGS [J].
BUSH, LR ;
BUJA, LM ;
TILTON, G ;
WATHEN, M ;
APPRILL, P ;
ASHTON, J ;
WILLERSON, JT .
CIRCULATION, 1985, 72 (02) :413-430
[5]   A PILOT TRIAL OF RECOMBINANT DESULFATOHIRUDIN COMPARED WITH HEPARIN IN CONJUNCTION WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI)-5 TRIAL [J].
CANNON, CP ;
MCCABE, CH ;
HENRY, TD ;
SCHWEIGER, MJ ;
GIBSON, RS ;
MUELLER, HS ;
BECKER, RC ;
KLEIMAN, NS ;
HAUGLAND, JM ;
ANDERSON, JL ;
SHARAF, BL ;
EDWARDS, SJ ;
ROGERS, WJ ;
WILLIAMS, DO ;
BRAUNWALD, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :993-1003
[6]   ENHANCEMENT OF THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY PRETREATMENT WITH HEPARIN [J].
CERCEK, B ;
LEW, AS ;
HOD, H ;
YANO, J ;
REDDY, NKN ;
GANZ, W .
CIRCULATION, 1986, 74 (03) :583-587
[7]   THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].
CHESEBRO, JH ;
KNATTERUD, G ;
ROBERTS, R ;
BORER, J ;
COHEN, LS ;
DALEN, J ;
DODGE, HT ;
FRANCIS, CK ;
HILLIS, D ;
LUDBROOK, P ;
MARKIS, JE ;
MUELLER, H ;
PASSAMANI, ER ;
POWERS, ER ;
RAO, AK ;
ROBERTSON, T ;
ROSS, A ;
RYAN, TJ ;
SOBEL, BE ;
WILLERSON, J ;
WILLIAMS, DO ;
ZARET, BL ;
BRAUNWALD, E .
CIRCULATION, 1987, 76 (01) :142-154
[8]  
DAVIES MJ, 1993, BRIT HEART J, V69, pS3
[9]   ACTIVATION OF PROTHROMBIN ACCOMPANYING THROMBOLYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
EISENBERG, PR ;
SOBEL, BE ;
JAFFE, AS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (05) :1065-1069
[10]   PARADOXIC ELEVATION OF FIBRINOPEPTIDE A AFTER STREPTOKINASE - EVIDENCE FOR CONTINUED THROMBOSIS DESPITE INTENSE FIBRINOLYSIS [J].
EISENBERG, PR ;
SHERMAN, LA ;
JAFFE, AS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (03) :527-529